Login to Your Account

GALNS Data Overshadowed

Carping Over PARPs: Buyout Equals 'Negative' for BioMarin?

By Jennifer Boggs

Monday, February 8, 2010
With promising early data and a clear Phase III pathway for its GALNS drug in a rare lysosomal storage disorder, BioMarin Pharmaceuticals Inc. said it is no longer in critical need of late-stage assets to fill out its pipeline. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription